News & Events
Published On: 6/17/2022
Target RWE Leads Industry Discussion of Fusion Designs and Teaching Advanced Epidemiologic Methods at SER 2022
Target RWE participated in several panels at this year’s Society for Epidemiological Research (SER) annual meeting that will help define the landscape of real-world data collection and analysis for years to come.
When gathering and analyzing large amounts of epidemiological data, researchers are often challenged with how to bring together different datasets in a way that yields meaningful and accurate results. Alexander Breskin, PhD, Senior Director of Statistics at Target RWE, presented research conducted with colleagues at UNC and UCLA during a symposium titled New Epidemiology of Fusion Designs, which introduced novel approaches that challenge conventional thinking about the limitations of how epidemiological studies are currently performed by highlighting principled approaches for combining data from different sources.
In his talk, Fusion Designs for Indirect Treatment Effects, Dr. Breskin demonstrated a new study design and analytic approach that allows researchers to compare treatments that were originally studied in separate clinical trials, thus expanding the range questions can be answered from existing, already collected data. This theoretically grounded approach combines data obtained from multiple sources and appropriately accounts for key factors that differ between their underlying populations, such as factors impacting a patient’s risk of adverse outcomes and adherence to medications.
“Often, studies that attempt to compare treatments used in different populations, such network meta-analyses, fail to account for important differences in the populations that impact the effects of the treatments. Here, we introduce a design and analytic approach, that we refer to as a ‘fusion design’, that is built on a strong theoretical foundation and is shown to provide valid estimates of these so-called ‘indirect treatment comparisons,’” said Dr. Breskin.
Lydia Feinstein, PhD, Senior Director of Epidemiology, is participating in the panel On Teaching Advanced Epidemiologic Methods, an important session that explores the content and tools used to teach epidemiology courses at leading academic institutions. Providing an essential industry perspective, Dr. Feinstein will join with experts in academia and government to weigh in on the importance of preparing students with the skills and thinking necessary to succeed in a competitive and rapidly evolving field.
Dr. Feinstein and Julia Ward, PhD, MPH, Senior Epidemiologist, will also be presenting findings from an important real-world analysis Disparities in Prevalence of Urinary Incontinence among a Nationally Representative Sample of Men, 2005-2016: Findings from the Urologic Diseases in America Project. The study found a high prevalence of urinary incontinence (UI) among a nationally representative population of men in the United States, with a disproportionate burden and a greater daily impact experienced by older men, those of a lower socioeconomic status, and Black men.
“This research contributes to a growing body of disparities research for men across racial and socioeconomic groups,” said Dr. Ward.
Contact us to learn more today!
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
08/25/2022New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)
08/24/2022Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest Acquisition
08/23/2022Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022
07/20/2022Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis Population
06/24/2022Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022